A review of our Top 10 sarcoma results from ASCO19 plus commentary from a specialist KOL in this niche
Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?
What can we learn from the recent data presented on Affimed's innate bispecific platform? A candid conversation with CEO, Dr Adi Hoess
Next generation IO molecules are likely to feature bispecific antibodies - can we address the weaknesses seen with immune agonist antibodies by switching modalities?
We saw a number of challenges emerge with immune agonists as antibodies and now companies are experimenting with them in bispecifics - what needs to be considered to make them work? What will the next wave of IO look like?
Can mRNA disrupt cancer therapy and boost responses beyond what we see with checkpoint therapy?
Is T cell therapy like Game of Thrones?
What can we learn from biomarkers and immune profiling in patients receiving bempeg, a CD122-directed pegylated IL-2 therapy
How is Synthorx's IL-2 cytokine THOR-707 different from other compounds in this niche?
How the design of different cancer approaches can affect clinical performance
Can we employ red blood cells in allogeneic, off-the-shelf cellular therapy products for the treatment of cancer?
New data suggests there may be value in targeting CD73 as well as the A2A receptor in certain tumour types...
Looking under the hood to find biomarkers of response and outcomes, ,
Thoughts on Macrogenics phase 3 SOPHIA trial exploring margetuximab vs. trastuzumab - hit or miss?
On KRAS in lung cancer, HRD in pancreatic cancer (not POLO) and genomics in RCC
A look at some of the hidden gems and struggling compounds in competitive niches at ASCO19
Insights from Day 2 of ASCO19, plus a look at what to expect in the plenary and other sessions today.
A review of some this key data presented including new compounds in early development and how they stack up against existing therapies.
Hidden gems - what to watch out for at ASCO19 off the beaten track amongst the wealth of data to peruse
A review of 7 different targets and 18 different compounds in the maturing and highly competitive bispecific niche.
Working out which are markers versus valid targets is going to be key in IO progress. Here we look at one particular candidate...
Exploring the many challenges associated with targeting KRASG12C and why we should temper enthusiasm for this niche
A review of the latest available TLR data and a look at an emerging biotech Silverback Therapeutics in this niche
A look a the updated adenosine pathway landscape and how it is progressing